Neglected tropical diseases

Freshpet Voluntarily Recalls One Lot of Freshpet® Select Small Dog Bite Size Beef & Egg Recipe Dog Food Due to Potential Salmonella Contamination

Saturday, June 12, 2021 - 6:51pm

BETHLEHAM, Pa., June 12, 2021 /PRNewswire/ --Freshpet Inc. is announcing a voluntary recall ofa single lot ofFreshpet SelectSmallDogBiteSizeBeef&EggRecipe Dog Food (1 LB bags), with Sell by Date 10/30/2021, due to potential contamination with Salmonella.

Key Points: 
  • BETHLEHAM, Pa., June 12, 2021 /PRNewswire/ --Freshpet Inc. is announcing a voluntary recall ofa single lot ofFreshpet SelectSmallDogBiteSizeBeef&EggRecipe Dog Food (1 LB bags), with Sell by Date 10/30/2021, due to potential contamination with Salmonella.
  • Our Freshpet Team had designated this single lot for destruction, but it was inadvertently shipped to retailers in limited geographic markets between June 7 and June 10, 2021.
  • Rarely,Salmonellacan result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary tract symptoms.
  • Sell by Date, along with UPC code and lot code, can be found on the bottom and back of each bag.

Global Neglected Tropical Diseases Diagnosis Market Research Report 2021 - ResearchAndMarkets.com

Friday, June 11, 2021 - 1:20pm

The "Neglected Tropical Diseases Diagnosis - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neglected Tropical Diseases Diagnosis - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Neglected Tropical Diseases Diagnosis estimated at US$6 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2027, growing at a CAGR of 4% over the period 2020-2027.
  • Conventional, one of the segments analyzed in the report, is projected to record 3.7% CAGR and reach US$4.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 6.4% CAGR
    The Neglected Tropical Diseases Diagnosis market in the U.S. is estimated at US$1.6 Billion in the year 2020.

Auransa and POLARISqb enter research collaboration finding treatments for neglected women's diseases

Friday, June 4, 2021 - 2:00pm

The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.

Key Points: 
  • The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.
  • Auransa is an AI-driven biotech company, with a pipeline of novel compounds for various diseases.
  • POLARISqb built the first drug discovery platform using quantum computing, making the process ten times faster.
  • We are thrilled to be able to combine our technology with Auransa's and tackle neglected diseases affecting women.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Wednesday, June 2, 2021 - 12:00pm

"As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.

Key Points: 
  • "As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.
  • Today's news will provide added peace of mind for physicians who choose KEDRAB in treating children who have possibly been exposed to rabies.
  • We are especially proud of our partnership with Kamada, which has resulted in this significant step forward in global health."
  • "Kamada is excited to have a HRIGthat can treat peopleof all ages in the U.S. with the FDA-approved label expansion for KEDRAB," said Amir London, Chief Executive Officer of Kamada.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Wednesday, June 2, 2021 - 12:00pm

The new updates to the KEDRAB label are based on data from the KEDRAB U .

Key Points: 
  • The new updates to the KEDRAB label are based on data from the KEDRAB U .
  • As the U.S. markets first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.
  • Todays news will provide added peace of mind for physicians who choose KEDRAB in treating children who have possibly been exposed to rabies.
  • We are especially proud of our partnership with Kamada, which has resulted in this significant step forward in global health.

BTG Specialty Pharmaceuticals Calls on Consumers and Retailers to Consider the Facts About Venom Extractors

Tuesday, April 20, 2021 - 4:57pm

These experts in the treatment of snakebites unanimously agree that venom extractors should not be used to treat snakebites.

Key Points: 
  • These experts in the treatment of snakebites unanimously agree that venom extractors should not be used to treat snakebites.
  • \xe2\x80\x9cBecause the extractors could cause an injury pattern, it goes against the physician\xe2\x80\x99s oath to do no harm.
  • The only effective and safe first aid treatment for a snakebite is a swift trip to the hospital.
  • Our current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

GLIDE Launches Inaugural Awards for Disease Elimination

Wednesday, April 14, 2021 - 4:00am

b'The Global Institute for Disease Elimination (GLIDE), a new Abu Dhabi-based global health Institute focused on eliminating infectious diseases of poverty, has launched The Falcon Awards for Disease Elimination, in a drive to discover and implement innovative approaches to disease elimination.\nFounded in 2019 by His Highness Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi, and the Bill & Melinda Gates Foundation, GLIDE identifies the latest scientific, cultural, and global health knowledge and puts it into action with partners through programmes to advance disease elimination.\nThe Falcon Awards, which open for submissions online on 4th May 2021, invites Non-Governmental Organisations (NGOs), philanthropic foundations, coalitions or networks of Civil Society Organisations (CSOs), academic or research institutions, Public-Private Partnerships (PPP), and public or private sector institutions in endemic countries to submit proposals that aim to accelerate the elimination of one or more of GLIDE\xe2\x80\x99s four focus diseases: malaria, polio, lymphatic filariasis, and onchocerciasis.\nGLIDE is particularly seeking proposals which address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

Key Points: 
  • b'The Global Institute for Disease Elimination (GLIDE), a new Abu Dhabi-based global health Institute focused on eliminating infectious diseases of poverty, has launched The Falcon Awards for Disease Elimination, in a drive to discover and implement innovative approaches to disease elimination.\nFounded in 2019 by His Highness Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi, and the Bill & Melinda Gates Foundation, GLIDE identifies the latest scientific, cultural, and global health knowledge and puts it into action with partners through programmes to advance disease elimination.\nThe Falcon Awards, which open for submissions online on 4th May 2021, invites Non-Governmental Organisations (NGOs), philanthropic foundations, coalitions or networks of Civil Society Organisations (CSOs), academic or research institutions, Public-Private Partnerships (PPP), and public or private sector institutions in endemic countries to submit proposals that aim to accelerate the elimination of one or more of GLIDE\xe2\x80\x99s four focus diseases: malaria, polio, lymphatic filariasis, and onchocerciasis.\nGLIDE is particularly seeking proposals which address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.
  • Submissions should focus on the implementation of innovative ideas and established research which has a high potential to be catalytic, transformational, or genuinely novel in approach, or on operational research with prospects to provide solutions to existing disease elimination challenges.\nSimon Bland, Chief Executive Officer of GLIDE, commented: \xe2\x80\x9cAt GLIDE, we firmly believe in an integrated and collaborative approach to tackling infectious diseases of poverty.
  • The Falcon Awards for Disease Elimination will help advance and amplify these efforts.\xe2\x80\x9d\nFive winners will be announced later this year following a thorough evaluation by a jury panel comprised of esteemed global health experts.
  • Each winner will receive a sum of up to USD200,000 to fund and implement their unique solutions to disease elimination.\nFor more information on The Falcon Awards and how to enter, please visit: https://glideae.org/awards\nThe Falcon Awards - key dates:\nGLIDE is a new global health Institute, rooted in Abu Dhabi, focused on accelerating the elimination of four preventable diseases of poverty: currently malaria, polio, lymphatic filariasis, and river blindness, by 2030 and beyond.

KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)

Thursday, March 25, 2021 - 5:23am

KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the Study) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the KD-382 vaccine), to prevent dengue*2.

Key Points: 
  • KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the Study) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the KD-382 vaccine), to prevent dengue*2.
  • The results show that the KD-382 vaccine is safe and well-tolerated by healthy adults.
  • KD-382 is a live attenuated tetravalent dengue vaccine that is expected to be effective against all four serotypes with a single dose.
  • Dengue virus is a mosquito-borne virus belonging to the Flaviviridae family and causes dengue fever, dengue hemorrhagic fever, and dengue shock syndrome in humans.

Global Orphan Assets Market Trends & Outlook Report 2020 - ResearchAndMarkets.com

Tuesday, March 16, 2021 - 10:15am

The "Market Trends for Orphan Assets: A Global Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Trends for Orphan Assets: A Global Outlook" report has been added to ResearchAndMarkets.com's offering.
  • 'Orphan drugs' are intended to treat rare/ultra rare diseases.
  • They are developed to treat patients suffering from very serious diseases for which no treatment, or adequate one, is available.
  • Rare disease patient populations in key launch markets are defined in law as:

NLR: Millions at risk of developing leprosy: new study predicts 40 million people need preventive treatment to eliminate leprosy in 22 years

Monday, March 1, 2021 - 3:00pm

Co-author Professor Jan Hendrik Richardus of Erasmus MC explains: "This study provides important insight into the challenge that remains to reach zero leprosy.

Key Points: 
  • Co-author Professor Jan Hendrik Richardus of Erasmus MC explains: "This study provides important insight into the challenge that remains to reach zero leprosy.
  • This study shows that to reduce the global number of new leprosy cases by 90% within 22 years, just over 40 million people who are at risk to develop leprosy require preventive treatment.
  • On a global scale, preventive treatment of 40 million people for leprosy is achievable if we coordinate our resources and efforts.
  • This should be done by targeting people most at risk of developing leprosy: close contacts (family, friends, neighbors) of new leprosy patients.